BlackBarn Capital Partners LP grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 107.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,050,000 shares of the company's stock after purchasing an additional 543,029 shares during the period. Teva Pharmaceutical Industries makes up 1.3% of BlackBarn Capital Partners LP's investment portfolio, making the stock its 4th biggest holding. BlackBarn Capital Partners LP owned about 0.09% of Teva Pharmaceutical Industries worth $23,142,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently made changes to their positions in TEVA. Diadema Partners LP acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $6,677,000. Hsbc Holdings PLC lifted its stake in shares of Teva Pharmaceutical Industries by 5.7% in the fourth quarter. Hsbc Holdings PLC now owns 561,289 shares of the company's stock valued at $12,374,000 after buying an additional 30,155 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Teva Pharmaceutical Industries by 33.3% during the fourth quarter. Stifel Financial Corp now owns 88,478 shares of the company's stock valued at $1,950,000 after buying an additional 22,087 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $37,689,000. Finally, MetLife Investment Management LLC raised its holdings in shares of Teva Pharmaceutical Industries by 40.4% in the 4th quarter. MetLife Investment Management LLC now owns 133,425 shares of the company's stock worth $2,941,000 after acquiring an additional 38,400 shares during the last quarter. Institutional investors own 54.05% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on TEVA. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Finally, UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $23.43.
Check Out Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Stock Performance
Shares of NYSE:TEVA traded up $0.16 during midday trading on Friday, reaching $14.88. The company had a trading volume of 6,566,648 shares, compared to its average volume of 9,929,030. The stock has a market cap of $16.87 billion, a P/E ratio of -10.26, a P/E/G ratio of 1.44 and a beta of 0.72. The company's 50 day moving average price is $15.23 and its 200 day moving average price is $17.56. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 52-week low of $12.47 and a 52-week high of $22.80.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.
Teva Pharmaceutical Industries Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Recommended Stories
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
